博晖创新(300318) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥159,179,087.52, a decrease of 42.99% compared to the same period last year[3]. - The net profit attributable to shareholders was -¥3,916,037.20, representing a decline of 147.69% year-over-year[3]. - The basic earnings per share (EPS) was -¥0.0048, down 147.52% from the previous year[3]. - Total operating revenue for Q3 2024 was ¥646,068,014.18, a decrease of 19.9% compared to ¥806,104,920.39 in Q3 2023[21]. - Net profit for Q3 2024 reached ¥45,007,016.93, compared to ¥14,422,884.59 in Q3 2023, representing a significant increase[22]. - The total comprehensive income attributable to the parent company for Q3 2024 is CNY 23,763,225.14, an increase from CNY 15,366,696.38 in the same period last year, representing a growth of approximately 54.5%[23]. - Basic and diluted earnings per share for Q3 2024 are both CNY 0.0290, up from CNY 0.0173 in the same period last year, reflecting an increase of approximately 67.7%[23]. Assets and Liabilities - Total assets increased to ¥4,115,135,732.47, reflecting a growth of 4.82% compared to the end of the previous year[3]. - The company's total assets increased to ¥4,115,135,732.47, up from ¥3,926,015,273.52 year-over-year[21]. - Non-current liabilities rose to ¥726,258,030.90, compared to ¥520,619,946.13 in the previous year, indicating a 39.4% increase[20]. - The total liabilities increased to ¥1,729,539,735.82, compared to ¥1,585,470,244.35 in the previous year, marking a 9.1% rise[20]. - Long-term borrowings rose by 61.29% to ¥549,880,314.57, attributed to increased bank loans by subsidiaries[7]. - The company's total equity attributable to shareholders increased by 1.74% to ¥1,393,301,767.52 compared to the end of the previous year[3]. - The total equity attributable to shareholders of the parent company was ¥1,393,301,767.52, an increase from ¥1,369,538,542.38 in the previous year[20]. Cash Flow - The cash flow from operating activities for the first nine months of 2024 was -¥12,088,916.80, a significant decrease of 111.67% year-over-year[10]. - The net cash flow from operating activities for Q3 2024 is CNY -12,088,916.80, a significant decrease compared to CNY 103,617,734.96 in Q3 2023[25]. - The total cash inflow from financing activities for Q3 2024 is CNY 1,048,461,585.92, down from CNY 1,428,966,671.91 in the previous year, indicating a decline of about 26.6%[26]. - The cash flow from investment activities for Q3 2024 is CNY -150,866,059.82, slightly worse than CNY -150,795,903.23 in the previous year[25]. - The total cash outflow from operating activities in Q3 2024 is CNY 730,052,111.70, compared to CNY 774,303,723.06 in Q3 2023, showing a decrease of about 5.7%[25]. - The cash and cash equivalents at the end of Q3 2024 amount to CNY 97,274,347.95, an increase from CNY 63,634,797.87 at the end of Q3 2023[26]. - The company's cash and cash equivalents increased to ¥118,363,873.12 from ¥104,925,738.92 at the beginning of the period, representing a growth of approximately 12.9%[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,750[11]. - The largest shareholder, Du Jiangtao, holds 39.03% of the shares, totaling 318,811,388 shares[12]. - The total number of shareholders with more than 5% ownership includes several individuals, with Du Jiangtao and Hao Hong being the most significant[12]. Operational Developments - The company obtained single plasma collection licenses for two subsidiaries, enhancing its operational capabilities[15]. - The respiratory pathogen six-fold nucleic acid detection kit received regulatory approval, expanding the product portfolio[15]. - The company signed a guarantee contract with China Construction Bank for a maximum of ¥326,582,300 to support its subsidiary[17]. - The company terminated a project cooperation contract related to rabies vaccine clinical trials, indicating a strategic shift in R&D focus[16]. Income and Expenses - The company's operating costs for the first nine months of 2024 were ¥318,826,772.88, down 31.05% from ¥462,435,519.21 in the same period last year[8]. - Total operating costs for Q3 2024 were ¥602,017,288.79, down 22.0% from ¥772,229,494.76 in the same period last year[21]. - Research and development expenses for Q3 2024 were ¥43,286,170.11, down from ¥53,646,814.14 in Q3 2023, reflecting a 19.4% decrease[21]. - Other income increased by 33.99% to ¥6,325,797.51, primarily due to government subsidies[8]. - The company reported a significant increase in non-operating income of 632.74%, totaling ¥18,276,629.93, mainly from compensation received for terminated clinical trials[9]. - Accounts receivable decreased to ¥41,083,685.84 from ¥53,895,164.57, indicating a decline of about 23.7%[18]. - Inventory increased significantly to ¥982,671,789.28 from ¥854,562,676.21, reflecting a rise of approximately 15%[18]. - The company reported a decrease in cash received from sales of goods and services, totaling CNY 672,247,502.42 in Q3 2024, down from CNY 838,698,516.96 in Q3 2023, a decline of approximately 19.8%[24].